A detailed history of New England Research & Management, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, New England Research & Management, Inc. holds 13,625 shares of BMRN stock, worth $894,617. This represents 0.45% of its overall portfolio holdings.

Number of Shares
13,625
Previous 9,075 50.14%
Holding current value
$894,617
Previous $747,000 28.25%
% of portfolio
0.45%
Previous 0.36%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$69.02 - $93.84 $314,041 - $426,972
4,550 Added 50.14%
13,625 $958,000
Q2 2024

Jul 09, 2024

SELL
$74.43 - $92.22 $467,048 - $578,680
-6,275 Reduced 40.88%
9,075 $747,000
Q1 2024

Apr 16, 2024

BUY
$83.81 - $99.0 $1.29 Million - $1.52 Million
15,350 New
15,350 $1.34 Million
Q1 2023

Apr 06, 2023

BUY
$87.74 - $117.27 $837,917 - $1.12 Million
9,550 New
9,550 $929,000
Q2 2022

Jul 20, 2022

SELL
$71.48 - $86.85 $669,267 - $813,176
-9,363 Closed
0 $0
Q1 2022

Apr 20, 2022

BUY
$74.28 - $92.69 $323,192 - $403,294
4,351 Added 86.81%
9,363 $722,000
Q4 2021

Jan 05, 2022

BUY
$71.72 - $91.47 $359,460 - $458,447
5,012 New
5,012 $443,000
Q1 2021

Apr 16, 2021

SELL
$74.73 - $90.69 $504,427 - $612,157
-6,750 Closed
0 $0
Q4 2020

Jan 07, 2021

BUY
$72.61 - $90.2 $490,117 - $608,850
6,750 New
6,750 $592,000
Q3 2019

Nov 04, 2019

SELL
$67.4 - $85.11 $212,310 - $268,096
-3,150 Closed
0 $0
Q2 2019

Jul 09, 2019

SELL
$80.35 - $93.9 $28,122 - $32,865
-350 Reduced 10.0%
3,150 $270,000
Q1 2019

Apr 03, 2019

BUY
$84.2 - $98.62 $294,700 - $345,170
3,500 New
3,500 $311,000
Q4 2018

Jan 11, 2019

SELL
$80.14 - $106.07 $440,770 - $583,385
-5,500 Closed
0 $0
Q3 2018

Oct 03, 2018

BUY
$93.92 - $105.72 $516,560 - $581,460
5,500 New
5,500 $533,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track New England Research & Management, Inc. Portfolio

Follow New England Research & Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New England Research & Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on New England Research & Management, Inc. with notifications on news.